310 related articles for article (PubMed ID: 32586039)
1. Bcr-Abl Tyrosine Kinase Inhibitors in the Treatment of Pediatric CML.
Carofiglio F; Lopalco A; Lopedota A; Cutrignelli A; Nicolotti O; Denora N; Stefanachi A; Leonetti F
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32586039
[TBL] [Abstract][Full Text] [Related]
2. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
[TBL] [Abstract][Full Text] [Related]
3. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
4. Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm.
Jabbour E; Kantarjian H; Cortes J
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):323-34. PubMed ID: 25971713
[TBL] [Abstract][Full Text] [Related]
5. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
Wongboonma W; Thongnoppakhun W; Auewarakul CU
Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255
[TBL] [Abstract][Full Text] [Related]
6. Perturbation of p38α MAPK as a Novel Strategy to Effectively Sensitize Chronic Myeloid Leukemia Cells to Therapeutic BCR-ABL Inhibitors.
Kuo YH; Wei SH; Jiang JH; Chang YS; Liu MY; Fu SL; Huang CF; Lin WJ
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830455
[TBL] [Abstract][Full Text] [Related]
7. [State-of-the-art management of CML in 2015 and future prospects].
Kimura S
Rinsho Ketsueki; 2015 Oct; 56(10):2005-14. PubMed ID: 26458439
[TBL] [Abstract][Full Text] [Related]
8. [Research Advance of
Zhou LY; Zhou LY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Apr; 31(2):585-588. PubMed ID: 37096538
[TBL] [Abstract][Full Text] [Related]
9. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.
An X; Tiwari AK; Sun Y; Ding PR; Ashby CR; Chen ZS
Leuk Res; 2010 Oct; 34(10):1255-68. PubMed ID: 20537386
[TBL] [Abstract][Full Text] [Related]
10. Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients.
Meggyesi N; Kozma A; Halm G; Nahajevszky S; Bátai A; Fekete S; Barta A; Ujj G; Lueff S; Sipos A; Adám E; Bors A; Reményi P; Masszi T; Tordai A; Andrikovics H
Acta Haematol; 2012; 127(1):34-42. PubMed ID: 22005133
[TBL] [Abstract][Full Text] [Related]
11. Clinical roundtable monograph: Emerging treatment options for TKI-resistant chronic myelogenous leukemia.
Cortes J; Radich J; Mauro MJ
Clin Adv Hematol Oncol; 2012 Oct; 10(10 Suppl 19):1-16. PubMed ID: 23187745
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of tyrosine kinase inhibitors on a mouse chronic myeloid leukemia model and chronic myeloid leukemia stem cells.
Tanaka Y; Fukushima T; Mikami K; Adachi K; Fukuyama T; Goyama S; Kitamura T
Exp Hematol; 2020 Oct; 90():46-51.e2. PubMed ID: 32910995
[TBL] [Abstract][Full Text] [Related]
13. Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia.
Bandyopadhyay S; Li J; Traer E; Tyner JW; Zhou A; Oh ST; Cheng JX
PLoS One; 2017; 12(7):e0179558. PubMed ID: 28719608
[TBL] [Abstract][Full Text] [Related]
14. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring.
Jabbour E; Kantarjian H
Am J Hematol; 2020 Jun; 95(6):691-709. PubMed ID: 32239758
[TBL] [Abstract][Full Text] [Related]
15. The landscape of BCR-ABL mutations in patients with Philadelphia chromosome-positive leukaemias in the era of second-generation tyrosine kinase inhibitors.
Chien SH; Liu HM; Chen PM; Ko PS; Lin JS; Chen YJ; Lee LH; Hsiao LT; Chiou TJ; Gau JP; Yang MH; Liu CY
Hematol Oncol; 2020 Aug; 38(3):390-398. PubMed ID: 32011024
[TBL] [Abstract][Full Text] [Related]
16. The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib.
Parker WT; Yeung DT; Yeoman AL; Altamura HK; Jamison BA; Field CR; Hodgson JG; Lustgarten S; Rivera VM; Hughes TP; Branford S
Blood; 2016 Apr; 127(15):1870-80. PubMed ID: 26773037
[TBL] [Abstract][Full Text] [Related]
17. Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation.
Tanaka R; Kimura S
Expert Rev Anticancer Ther; 2008 Sep; 8(9):1387-98. PubMed ID: 18759691
[TBL] [Abstract][Full Text] [Related]
18. In-silico identification of inhibitors against mutated BCR-ABL protein of chronic myeloid leukemia: a virtual screening and molecular dynamics simulation study.
Kumar H; Raj U; Gupta S; Varadwaj PK
J Biomol Struct Dyn; 2016 Oct; 34(10):2171-83. PubMed ID: 26479578
[TBL] [Abstract][Full Text] [Related]
19. ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives.
Massimino M; Stella S; Tirrò E; Pennisi MS; Vitale SR; Puma A; Romano C; DI Gregorio S; Tomarchio C; DI Raimondo F; Manzella L
Anticancer Res; 2020 May; 40(5):2457-2465. PubMed ID: 32366389
[TBL] [Abstract][Full Text] [Related]
20. Chronic myeloid leukemia stem cells and molecular target therapies for overcoming resistance and disease persistence.
Inoue A; Kobayashi CI; Shinohara H; Miyamoto K; Yamauchi N; Yuda J; Akao Y; Minami Y
Int J Hematol; 2018 Oct; 108(4):365-370. PubMed ID: 30155588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
